Applied Therapeutics, Inc. APLT · Stock Open Applied Therapeutics, Inc. in new tab
Applied Therapeutics, Inc. Analysis (APLT)
Is Applied Therapeutics, Inc. a good investment? Applied Therapeutics, Inc. (APLT) is currently trading at 0.1030 USD.
Earnings Schedule: Applied Therapeutics, Inc. is expected to release its next earnings report on April 13, 2026. The market consensus estimate for Forward EPS is -0.40.
Investor FAQ
Does Applied Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Applied Therapeutics, Inc.?
Applied Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be April 13, 2026. The company currently has a trailing EPS of -0.10.
Company Profile
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. As of February 3, 2026, Applied Therapeutics, Inc. operates as a subsidiary of Cycle Group Holdings Limited.
Community Discussion